NEW YORK, March 23, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Natus Medical Incorporated (“Natus” or the “Company”) (NASDAQ:BABY) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Natus Medical Incorporated securities between October 16, 2015 and April 3, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/baby.
The class action lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose material adverse facts about Natus’ business, operations, and prospects, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) consequently, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis. Once this information was made known to the investing public, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/baby or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Natus you have until March 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable”
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 



